ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag sexual antagonism microbiology immunology cell molecular biology neuroscience

The AIDS Research Evaluators
Lynn Gambale | Jul 9, 1995 | 6 min read
Chairman: Arnold Levine, chairman, department of molecular biology, Princeton University Barry Bloom, Weinstock Professor and Howard Hughes Medical Institute (HHMI) investigator, department of microbiology and immunology, Albert Einstein College of Medicine, New York Rebecca Buckley, professor of pediatrics and immunology, Duke University Medical Center Charles Carpenter, chairman, Office of AIDS Research Advisory Committee; professor of medicine,Brown University School of Medicine Don
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Those We Lost in 2018
Ashley Yeager | Dec 26, 2018 | 10+ min read
The scientific community said goodbye to a number of leading researchers this year.
Notebook
Ricki Lewis | Apr 11, 1999 | 7 min read
Peanuts may be losing their bite PEANUT ALLERGY VACCINE Peanuts are more than just an annoyance on airplanes--for a few dozen people each year, they cause deadly anaphylactic shock. The only protection is knowledge of one's allergy and avoidance of the offending food. But most peanut-associated allergic deaths occur from peanut extracts added to prepared foods--additives that sometimes remain unlisted on labels. A peanut allergy vaccine could prevent such deaths. Kam Leong, a professor of biom
An 'Iterative Process'
Billy Goodman | Jul 9, 1995 | 7 min read
Sidebar: The AIDS Research Evaluators The 100-plus members of a newly constituted National Institutes of Health task force have begun their daunting task: a comprehensive reevaluation of NIH's entire $1.4 billion AIDS portfolio, including both intramural and extramural research. Compounding the challenge for the scientists and AIDS activists who make up the task force is a withering schedule. They will have to produce a report due in January 1996, to aid in planning the 1998 Office of AIDS Rese

Run a Search

ADVERTISEMENT